Iambic Therapeutics, Inc. - 10-Q Filing

Iambic Therapeutics reports Q3 2025 financial results featuring significant R&D and G&A expenditures alongside ongoing collaboration agreements with AbbVie, Bayer, Lundbeck, and Takeda.

SEC EDGAR ·

Tickers: $IAM

Read the full article at SEC EDGAR

More Regulatory news